Literature DB >> 14717484

Stepwise surgical approach for in vivo expansion of epithelial stem cells to treating severe acute chemical burns with total limbal deficiency.

Gun Sic Park1, Juan Je, Jae Chan Kim.   

Abstract

To describe the clinical outcome of a new surgical treatment for the acute stages of severe corneal burn injury and its complications, a prospective study of five acute corneal burn patients with severe limbal damage was performed. Amniotic membrane transplantation (AMT) and conjunctival limbal autograft (CLAU) was performed at the acute stage of corneal burn injury to reconstruct the damaged ocular surface (step I). Three to six months later, the opaque central part of the amniotic membrane containing in vivo grown corneal stem cells were removed and retransplanted to the defect created after the removal of pseudopterygium (step II). All injured eyes were successfully treated, but in one eye with marked stromal lysis, three-layered AMT and penetrating keratoplasty with retransplantation of in vivo grown corneal stem cells was performed. In the former cases, visual acuity was greatly improved more than three lines (ranging from 3 to 12 lines). In short, retransplantation of in vivo grown corneal stem cells after AMT and CLAU is a recommendable modality for restoring a stable corneal epithelium of a severely burned ocular surface in the acute stage and can be considered a preventative measure for avoiding late onset complications.

Entities:  

Mesh:

Year:  2003        PMID: 14717484     DOI: 10.3341/kjo.2003.17.2.75

Source DB:  PubMed          Journal:  Korean J Ophthalmol        ISSN: 1011-8942


  2 in total

1.  Ultrastructural analysis of in vivo expanded corneal epithelium on amniotic membrane.

Authors:  Hyo Shin Ha; Kye Yong Song; Jae Chan Kim
Journal:  J Korean Med Sci       Date:  2006-06       Impact factor: 2.153

Review 2.  The application of human amniotic membrane in the surgical management of limbal stem cell deficiency.

Authors:  Qihua Le; Sophie X Deng
Journal:  Ocul Surf       Date:  2019-01-08       Impact factor: 5.033

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.